在患有初级多药耐药性性综合征的幼儿中,成功治疗了Obinutuzumab
Magdalena Drozynska-Duklas1, Ilona Zagozdzon1, Ilona Chudzik1
1Department of Paediatrics, Nephrology and Hypertension, Medical University of Gdansk, 80-210 Gdansk, Poland.
Journal of clinical medicine
|January 10, 2026
概括
奥比努图祖马布成功治疗了一名患有耐固醇性性综合征 (SRNS) 的幼儿,该综合征对其他疗法不耐药. 这表明obinutuzumab作为重症,耐治疗的SRNS在儿科患者的潜在救援选择.
科学领域:
- 儿科脏病学 儿科脏病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 儿童类固醇耐药性性综合征 (SRNS) 存在诊断和治疗方面的挑战,通常与年轻患者的遗传因素有关.
- 有限的治疗选择和不良预后是SRNS的特征,需要探索新的治疗策略.
- 目前的指导方针建议对年轻的SRNS患者进行基因检测和感染治疗,对年长的儿童考虑使用抗CD20疗法.
研究的目的:
- 报告在患有初级SRNS的非常年幼儿童中首次成功使用obinutuzumab.
- 评估奥比努图祖马布作为儿童患者多药耐药SRNS的潜在救援疗法.
主要方法:
- 一名24个月大的男孩患有严重的,复杂的SRNS耐火性循环素A和修复剂,两周间隔接受了两剂奥比努图祖马布 (300 mg/m2 BSA).
- 之前的基因测试和传染病检查结果呈阴性,表明可疑的免疫病因.
- 对蛋白尿和血清白蛋白水平的治疗反应进行了监测.
主要成果:
- 在治疗后两个月,严重性综合征的完全缓解得到了实现.
- 在没有进一步的免疫抑制药物的情况下,观察到蛋白尿持续消失和血清白蛋白水平正常.
- 在治疗期间没有报告严重的不良反应.
结论:
- 奥比努图祖马布在幼儿中显示出作为重症多药耐药性异常性性综合征 (INS) 的救援疗法的潜力.
- 这一案例凸显了奥比努图祖马布作为一种可行的选择,当传统治疗失败,其他病因被排除在外时.
相关概念视频
01:26Nephrotic Syndrome II : Assessment and Medical Management
189
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
189
01:24Nephrotic Syndrome III : Nursing Management
276
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
276
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
201
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
201
01:24Nephrotic Syndrome I : Introduction
486
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
486
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
475
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
475
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
239
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
239